NImmune Biopharma Reported LANCL2 Drug Trial Results
New preclinical and clinical data suggest LANCL2-targeting therapies could improve outcomes for patients refractory to biologics.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust that artificial intelligence will lead to safer and more effective medical treatments?
NImmune Biopharma presented research at the American College of Gastroenterology 2026 meeting detailing the performance of oral LANCL2-targeting medicines omilancor and NIM-1324. These findings, which include human clinical data and preclinical results, are currently in the research stage.
Why it matters
These studies address inflammatory, metabolic, and fibrotic processes that contribute to treatment resistance in IBD patients. The research aims to expand therapeutic options for those who fail to respond to standard biologic interventions.
A 12-week study of omilancor demonstrated a 55% reduction in a 78-gene signature linked to biologic nonresponse. The drug achieved this by decreasing gene expression levels by more than two-fold compared to baseline measurements.
The players
NImmune Biopharma
A Blacksburg, Virginia-based firm leveraging the TITAN-X platform to discover and develop treatments for IBD and bacterial infections.
American College of Gastroenterology
A professional medical association that hosts an annual scientific meeting for gastrointestinal research.
The details
The medicines function by targeting LANCL2, a protein involved in regulating immune pathways. To determine efficacy, researchers used the TITAN-X platform, which integrates artificial intelligence, computational modeling, and bioinformatics to map disease pathways. This computational approach allows for the identification of a 78-gene signature specifically associated with inflammation and failure to respond to existing biologic therapies.
Timeline
The American College of Gastroenterology 2026 Annual Scientific Meeting took place in 2026.
The omilancor clinical presentation study spanned a duration of 12 weeks.
The Tech Race
The study marks the application of the TITAN-X platform to the problem of biologic-refractory disease. This effort follows a research trajectory aimed at reducing discovery timelines by identifying pathways through AI-driven modeling.
Patients currently struggling with treatment-resistant IBD may see future benefits if these oral, once-daily therapies reach clinical approval. Availability and pricing remain unannounced as the company continues to progress these compounds through the development pipeline.
The takeaway
These findings underscore the potential for AI-driven computational modeling to overcome biologic resistance in IBD. Stakeholders should monitor future clinical trial results to see if the reduction in gene expression markers translates into sustained clinical remission.
Further reading
Learn more about the latest research in this sector on our Biotech page.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that artificial intelligence will lead to safer and more effective medical treatments?
